-
Kenya's economy faces climate change risks: World Bank
-
US Fed expected to hold rates steady as Iran war roils outlook
-
It's 'Sinners' v 'One Battle' as Oscars day arrives
-
US mayors push back against data center boom as AI backlash grows
-
Who covers AI business blunders? Some insurers cautiously step up
-
Election campaign deepens Congo's generational divide
-
Courchevel super-G cancelled due to snow and fog
-
Middle East turmoil revives Norway push for Arctic drilling
-
Iran, US threaten attacks on oil facilities
-
Oscars: the 10 nominees for best picture
-
Spielberg defends ballet, opera after Chalamet snub
-
Kharg Island bombed, Trump says US to escort ships through Hormuz soon
-
Jurors mull evidence in social media addiction trial
-
UK govt warns petrol retailers against 'unfair practices' during Iran war
-
Mideast war cuts Hormuz strait transit to 77 ships: maritime data firm
-
How will US oil sanctions waiver help Russia?
-
Oil stays above $100, stocks slide tracking Mideast war
-
How Iranians are communicating through internet blackout
-
Global shipping industry caught in storm of war
-
Why is the dollar profiting from Middle East war?
-
Oil dips under $100, stocks back in green tracking Mideast war
-
US Fed's preferred inflation gauge edges down
-
Deadly blast rocks Iran as leaders attend rally in show of defiance
-
Moscow pushes US to ease more oil sanctions
-
AI agent 'lobster fever' grips China despite risks
-
Thousands of Chinese boats mass at sea, raising questions
-
Casting directors finally get their due at Oscars
-
Fantastic Mr Stowaway: fox sails from Britain to New York port
-
US jury to begin deliberations in social media addiction trial
-
NASA says 'on track' for Artemis 2 launch as soon as April 1
-
Valentino mixes 80s and Baroque splendour on Rome return
-
Dating app Tinder dabbles with AI matchmaking
-
Scavenging ravens memorize vast tracts of wolf hunting grounds: study
-
Top US, China economy officials to meet for talks in Paris
-
Chile's Smiljan Radic Clarke wins Pritzker architecture prize
-
Lufthansa flights axed as pilots walk out
-
Oil tops $100 as fresh Iran attacks offset stockpiles release
-
US military 'not ready' to escort tankers through Hormuz Strait: energy secretary
-
WWII leader Churchill to be removed from UK banknotes
-
EU vows to 'respond firmly' to any trade pact breach by US
-
'Punished' for university: debt-laden UK graduates urge reform
-
Mideast war to brake German recovery: institute
-
China-North Korea train arrives in Pyongyang after 6-year halt
-
Businessman or politician? Billionaire Czech PM under fire again
-
Lost page of legendary Archimedes palimpsest found in France
-
Cathay Pacific roughly doubles fuel surcharge on most routes
-
BMW profit holds up despite Trump tariffs, China woes
-
Electric vehicle rethink to cost Honda almost $16 billion
-
From Kyiv to UK, Ukrainian drone production spans Europe
-
Australia to change fuel quality standards to boost supply
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.K.Baumgartner--CPN